IPRO (IFF1 Platform Research Optimisation) v1.0
Research type
Research Study
Full title
IFF1 Platform Research Optimisation (IPRO): An exploratory platform trial to evaluate dietary supplements and their impact on digestive, metabolic and immune health
IRAS ID
358911
Contact name
John Luke Twelves
Contact email
Sponsor organisation
Danisco Sweeteners Oy, a wholly owned subsidiary of International Flavors & Fragrances Inc, (IFF)
Duration of Study in the UK
10 years, 0 months, 2 days
Research summary
This research study aims to understand how dietary supplements (primarily probiotics) might improve health markers in three key areas: digestion, metabolism (how the body processes food and sugar), and immune function. The study targets adults aged 35-70 years who experience symptoms such as stress or fatigue, have insufficient fruit and vegetable intake, are less physically active, and have at least one health concern (elevated HbA1c 39-46 mmol/mol inclusive or gastrointestinal complaints).
Each participant undergoes a 6-week intervention period with assessments at baseline, week 3, and week 6. Participants will:
Take part in remote screening activities for up to 1 week (to determine suitability to take part)
Wear a glucose monitor for 2 weeks at the start of treatment and 2 weeks at the end of treatment
Take dietary supplements (or placebo) daily for 6 weeks at home
Visit a clinic in London 3 times for blood tests
Complete online surveys and questionnaires about symptoms and quality of life
Provide stool and vaginal samples (women only) at home
Measure their weight and waist/hip circumference at home
Why is this research important?
The gut contains trillions of bacteria that influence our overall health. This study uses an innovative "platform" design that allows researchers to test multiple dietary products which may impact the gut microbiome efficiently. This approach could help identify which specific supplements work best for different health conditions.
What are the benefits?
Participants receive between £261-£333 compensation for their time and travel expenses. The results may help develop better dietary supplements for common health problems affecting digestion, metabolism, and immune function.
The study is funded by Danisco Sweeteners Oy, a wholly owned subsidiary of International Flavors & Fragrances Inc (IFF) and conducted by Lindus Health.REC name
South Central - Hampshire A Research Ethics Committee
REC reference
25/SC/0394
Date of REC Opinion
30 Jan 2026
REC opinion
Further Information Favourable Opinion